MUTI-BIC 4 MMOL/L POTASIUM
FRESENIUS CARE DEUTSCHLAND
Identification
- Active ingredient (INN)
- SOLUTION A CHLORURE DE POTASSIUM/CHLORURE DE CALCIUM DIHYDRATE/CHLORURE DE MAGNESIUM HEXAHYDRATE/GLUCOSE ANHYDRE S/F MONOHYDRATE SOLUTION B CHLORURE DE SODIUM/BICARBONATE DE SODIUM
- Internal code
- 25 G 075
- Country of Origin
- Germany
- Pharmaceutical form
- Hemofiltration Solution
- Prescription List
- Highly Regulated (List I)
- Packaging
- poche de 05 l bi-compartimentee a ( 0.25 l) et b( 4.75 l)
DAWA Clinical Workbench v2.0
Information may not be accurate. Always consult a physician, pharmacist, or specialist before acting on any data shown here.
Description
Methylene blue is an oxidation-reduction agent.
The intravenous form of methylene blue is approved by the FDA for the treatment of pediatric and adult patients with acquired methemoglobinemia.
Historically, it has been widely used in Africa to treat malaria, but now it disappeared when chloroquine (CQ) and other drugs entered the market.
Its use as an urinary tract antiseptic has also been investigated.
Methylthioninium chloride (INN, or methylene blue, proposed trade name Rember) is an investigational drug being developed by the University of Aberdeen and TauRx Therapeutics that has been shown in early clinical trials to be an inhibitor of Tau protein aggregation.
The drug is of potential interest for the treatment of patients with Alzheimer's disease.
Indications
Indicated for the treatment of pediatric and adult patients with acquired methemoglobinemia.
Other clinical applications of methylene blue include improvement of hypotension associated with various clinical states, an antiseptic in urinary tract infections, treatment of hypoxia and hyperdynamic circulation in cirrhosis of liver and severe hepatopulmonary syndrome, and treatment of ifofosamide induced neurotoxicity.
Mechanism of Action
Guanylate cyclase soluble subunit alpha-2 Inhibitor Nitric oxide synthase 1 Inhibitor.
Metabolism
Following distribution into tissues, rapidly reduced to leukomethylene blue (leucomethylthioninium chloride).
Metabolism to leucomethylene blue may be less efficient in neonates than in older individuals.
Route of Elimination
Excreted in urine and bile.
About 75% of an oral dose excreted in urine, primarily as stabilized colorless leukomethylene blue.
Half-life
5–6.5 hours (after Intravenous dose).
Adverse Effects
Improve decision support & research outcomes With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.
View sample adverse effects data in our new Data Library! See the data Improve decision support & research outcomes with our structured adverse effects data.
Warnings
Warnngs For external use only
Do not use ■ if this product changes color or becomes cloudy ■ if seal is broken or punctured When using this product ■ do not touch tip of container to any surface to avoid contamination ■ replace cap after each use Stop use and consult a physician if you experience any of the following ■ eye pain ■ changes in vision ■ irritation or redness for longer than 72 hours If pregnant or breast-feeding, ask a health professional before use.
Do not use if this product changes color or becomes cloudy if you are sensitive to any ingredient in this product When using this product do not touch the tip of container to any surface to avoid contamination replace cap after each use Stop use and consult a physician if you experience any of the following: eye pain changes in vision occur irritation or redness for longer than 72 hours Keep out of reach of children If swallowed, get medical help or contact a Poison Control Center right away If pregnant or breastfeeding ask a health professional before use.
Dosage & Administration
Instill 1 or 2 drops in the affected eye(s) as needed.
Pregnancy
If pregnant or breastfeeding ask a health professional before use.